ORIENTBIO Inc.
Financials
Valuation Metrics
ORIENTBIO Inc.'s Market Cap is ₩359B. At end of 2025 it was ₩755B. Ranked #1918 of 2,405 in KR market (top 80%), #721 of 778 on KOSPI (top 93%), #204 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 35.90B KRW | KR#1,918/2,405 Sec#204/231 |
| Revenue | 29.75B KRW | KR#2,027/2,405 Sec#140/231 |
| Net Income | -4.57B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 81.62B KRW | KR#1,922/2,405 Sec#159/231 |
| Net Assets | 68.54B KRW | KR#1,698/2,405 Sec#145/231 |
| Employees | 106 | KR#1,597/2,405 Sec#125/231 |
| Value | ||
| P/B | 0.52x | KR#922/2,405 Sec#51/231 |
| P/S | 1.21x | KR#1,551/2,405 Sec#90/231 |
| FCF Yield | 1.53% | KR#1,098/2,405 Sec#75/231 |
| Profitability | ||
| ROE | -6.66% | KR#1,847/2,405 Sec#133/231 |
| ROA | -5.60% | KR#1,955/2,405 Sec#143/231 |
| Op. Margin | -13.89% | KR#2,043/2,405 Sec#139/231 |
| Revenue Growth | 1.21% | KR#1,435/2,405 Sec#143/231 |
| Financial Health | ||
| Debt Ratio | 19.07% | KR#341/2,405 Sec#46/231 |
| FCF | 547.9M KRW | KR#1,176/2,405 Sec#90/231 |
| Cash | 5.83B KRW | KR#1,948/2,405 Sec#177/231 |
| Current Ratio | 7.82x | KR#147/2,405 Sec#31/231 |
| Performance | ||
| 1Y Return | -47.98% | KR#1,879/2,405 Sec#160/231 |
| 1M Return | -26.16% | KR#2,125/2,405 Sec#211/231 |
| From 52W High | -65.00% | KR#1,888/2,405 Sec#159/231 |
| 1Y MDD | -60.19% | KR#1,448/2,405 Sec#116/231 |
| Trading | ||
| Volume | 13,300 shares | KR#1,715/2,405 Sec#167/231 |
| Trading Value | 16.1M KRW | KR#2,149/2,405 Sec#219/231 |
| Foreign Own. | 0.42% | KR#2,220/2,405 Sec#214/231 |
| Per Share | ||
| EPS | -154 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,312 KRW | KR#2,008/2,405 Sec#164/231 |
Company Info
Established in 1959, the company merged with Biogenomics in 2003 and spun off its watch business in 2005. It operates in laboratory animal production and life science research and development, holding a technical alliance with Charles River Laboratories. The company produces high-quality biological resources using Korea's largest land area and breeding facilities, and also runs a laboratory equipment CRO business. It is dedicated to enhancing technological competitiveness through bio-industry facility construction, advanced equipment development, and clinical trials for new hair loss drugs. Orient Bio is headquartered in Seongnam-si, Gyeonggi.